Diabetes, a world public health concern

Ingredia launched Pep2Dia®, specifically developed to help manage blood sugar level. This patented milk protein hydrolysate has an active dipeptide AP, which inhibits the alpha glucosidase. Preclinical and clinical studies have proven the efficacy of Pep2Dia® to reduce glycaemia after a meal.

Today more than 350 million people live with high blood sugar glucose (1). In 5 to 10 years, if nothing is done, the people with prediabetes, who have a higher-than-normal glycaemia in the morning fasting, will become diabetic. Everywhere, diabetes is on the rise and affects 8.5% of the adult population (2).

Diabetes leads to adverse effects on health, and in the long run can affect eyes, kidneys, feet, and cause heart conditions or stroke. This chronic disease is one of the causes of premature mortality but type 2 diabetes can be avoided because prediabetes is reversible!

Pep2Dia®, an innovative bioactive to delay the onset of type 2 diabetes, regulates blood sugar levels after meals.

Pep2Dia® is a patented (3) milk protein hydrolysate with an active dipeptide AP, specifically designed for prediabetes, to help manage blood sugar. AP peptide acts as an inhibitor of the alpha glucosidase. This digestive enzyme hydrolyses polysaccharides into glucose and allows absorption. Its inhibition lowers blood sugar levels.

Pep2Dia® is the result of extensive research and collaboration between Ingredia’s scientists and LIENSs-CNRS La Rochelle University in France.

Pep2Dia® has proven efficacy on glycaemia after meals.

Pre-clinical and clinical studies support Pep2Dia®’s action to reduce postprandial glycaemia with a significative effect versus the placebo.

To prevent Type 2 diabetes change your food habits, exercise and take … Pep2Dia®!

References:
1) International Diabetes Fundation, Atlas 2018